levofloxacin has been researched along with Communicable Diseases, Emerging in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Eroğlu, C; Günaydın, M; Güney, AK; Karadağ, A; Usta, E; Yanık, K | 1 |
2 other study(ies) available for levofloxacin and Communicable Diseases, Emerging
| Article | Year |
|---|---|
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
[Investigation of the presence of class 1, 2, 3 integrons and their relationships with antibiotic resistance in clinical Stenotrophomonas maltophilia isolates].
Topics: Anti-Infective Agents; Ceftazidime; Chloramphenicol; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Integrons; Levofloxacin; Opportunistic Infections; Plasmids; Stenotrophomonas maltophilia; Trimethoprim, Sulfamethoxazole Drug Combination | 2015 |